Kutatási jelek – Signal Engine

• Can Patients With Recurrent or Primary Squamous Cell Carcinoma of the Anus in a Previously Irradiated Pelvis Receive Definitive Reirradiation? — Anal squamous cell carcinoma
• Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT‑ION): an open‑label, single‑arm, phase 2 trial — Gastrointestinal stromal tumor
• Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapies — Melanoma
• Advances in Uveal Melanoma: From Molecular Pathogenesis to Precision Diagnostics and Personalized Therapies: Narrative Overview — Melanoma
• Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses — Chronic myeloid leukemia
• HPV-Negative Basaloid Squamous Cell Carcinoma of the Rectum: An Exceptionally Rare Entity — Colorectal cancer
• Effect of delayed treatment on survival of patients with head and neck squamous cell cancer — Head and neck squamous cell carcinoma
• Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021 — Thyroid cancer
• Oncological Management of Adrenocortical Carcinoma: An Update and Critical Review — Adrenocortical carcinoma
• Early positron emission tomography response‑adapted treatment in low‑risk diffuse large B‑cell lymphoma: an open‑label, multicenter, randomized, noninferiority phase III trial — Diffuse large B-cell lymphoma
• Is There a Role for Mifamurtide in Nonmetastatic High‑Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS‑2) and Spanish Sarcoma Group (GEIS‑33) Trials — Osteosarcoma
• Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study — Multiple myeloma
• Diffuse large B‑cell lymphoma in the new era: prognostic tools for mapping risk — Diffuse large B-cell lymphoma
• Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report — Diffuse large B-cell lymphoma
• Inferior orbital adenoid cystic carcinoma with skull base and cranial nerves infiltration-case report — Head and neck squamous cell carcinoma
• Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint — Chronic myeloid leukemia
• Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties — Chronic myeloid leukemia
• Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025 — Chronic myeloid leukemia
• Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials — Endometrial cancer
• Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium — Ewing sarcoma